Stephen Elledge's Harvard lab takes $17M to birth ImmuneID, a high-throughput antibody startup
Lea Hachigian, a principal at the Longwood Fund, recalls working with Harvard professor Stephen Elledge three years ago on the launch of TCR-focused TScan Therapeutics. Elledge initially set out to screen antigen-TCR matches in a faster, more systematic way and spent seven years putting together the tech for a platform that could run multiple T cell receptors against antigen epitopes and pinpoint the exact pairs that appear to interact.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.